This article was originally published on
Although frontline maintenance treatment with fuzuloparib monotherapy produced a progression-free survival (PFS) benefit in patients with newly diagnosed advanced
Fuzuloparib Monotherapy Improves PFS in Advanced Ovarian Cancer, but Adding Apatinib Offers No Additional Benefit
